Idamycin PFS, illustration of pre-filled syringe form (not a photo of the actual pack)

Illustrative image.

Idamycin PFS

Idarubicin Hydrochloride

Prescription required

$165.00

10mg · 1 syringes

BrandBranded medicine· By Pfizer

Choose a pack

  • Selected pack

Packs in this delivery

1

Test mode: no payment is taken. View cart

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

FDA boxed warningCardiomyopathy, secondary malignancies, and extravasation and tissue necrosis

Cardiomyopathy: IDAMYCIN PFS can cause myocardial damage, including acute left ventricular failure, during or after termination of therapy. The risk of cardiomyopathy is increased in patients who have received prior anthracyclines or who have pre-existing cardiac disease. Assess left ventricular cardiac function prior to initiation of IDAMYCIN PFS and during and after treatment.

Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including IDAMYCIN PFS.

Extravasation and Tissue Necrosis: Extravasation of IDAMYCIN PFS during administration can result in local tissue injury and necrosis. Immediately terminate the infusion of IDAMYCIN PFS and institute the recommended management procedures.

Cardiomyopathy: Myocardial damage leading to congestive heart failure can occur with IDAMYCIN PFS. Assess left ventricular cardiac function prior to initiation of IDAMYCIN PFS and during and after treatment.

Extravasation of IDAMYCIN PFS during administration can result in local tissue injury and necrosis. Immediately discontinue the IDAMYCIN PFS infusion if extravasation occurs.

Read this with the rest of the clinical information

About Idamycin PFS

Overview

Idamycin PFS contains idarubicin hydrochloride, an anthracycline chemotherapy medicine. It is used with other chemotherapy medicines to treat adults with acute myeloid leukemia (AML). It works by damaging DNA and interfering with processes cells need to divide.

What it treats

Acute myeloid leukemia (AML) in adults, as part of a combination chemotherapy regimen.

Safety information

Side effects

Common side effects include infections, nausea and vomiting, hair loss, abdominal pain and diarrhea, bleeding, inflammation of the mouth and other mucous membranes, skin problems, changes in mental state, and lung problems. Serious side effects that warrant contacting a doctor include heart muscle damage, new cancers, severe tissue damage if the medicine leaks outside a vein, and severe suppression of blood cell production. This suppression can lead to severe infection, septic shock, bleeding, or death. Other serious risks include tumor lysis syndrome and hypersensitivity reactions. Blood counts, blood chemistry, kidney function, and liver function need monitoring during treatment. Idamycin PFS can harm an unborn baby. Use effective contraception and contact your doctor if you become pregnant during treatment.

FDA boxed warning

Cardiomyopathy, secondary malignancies, and extravasation and tissue necrosis

Cardiomyopathy: IDAMYCIN PFS can cause myocardial damage, including acute left ventricular failure, during or after termination of therapy. The risk of cardiomyopathy is increased in patients who have received prior anthracyclines or who have pre-existing cardiac disease. Assess left ventricular cardiac function prior to initiation of IDAMYCIN PFS and during and after treatment.

Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including IDAMYCIN PFS.

Extravasation and Tissue Necrosis: Extravasation of IDAMYCIN PFS during administration can result in local tissue injury and necrosis. Immediately terminate the infusion of IDAMYCIN PFS and institute the recommended management procedures.

Cardiomyopathy: Myocardial damage leading to congestive heart failure can occur with IDAMYCIN PFS. Assess left ventricular cardiac function prior to initiation of IDAMYCIN PFS and during and after treatment.

Extravasation of IDAMYCIN PFS during administration can result in local tissue injury and necrosis. Immediately discontinue the IDAMYCIN PFS infusion if extravasation occurs.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

Seek medical attention immediately if you notice: • Unexpected bleeding. • New or worsening breathing problems. • New confusion or other changes in thinking or awareness. • Severe abdominal pain, diarrhea or vomiting. • Skin or tissue damage around the infusion site.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

The label lists no formal contraindications. However, Idamycin PFS should be avoided in patients with serum bilirubin above 5 mg/dL, a marker of liver impairment. Treatment requires close monitoring because it can severely reduce blood cell counts, leading to serious infection, septic shock, bleeding or death. Complete blood counts are needed before each treatment. Kidney and liver function should be checked before and during treatment, with particular caution in patients with kidney or liver impairment. Patients also need monitoring for tumor lysis syndrome and hypersensitivity reactions. Idamycin PFS can harm an unborn baby. Patients should use effective contraception and be advised of the risk to a fetus. Do not breastfeed during treatment. The medicine may impair fertility.

Using Idamycin PFS

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store in the original carton to protect it from light. Check the pack for whether it must be refrigerated before first use. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label IDAMYCIN PFS (IDARUBICIN HYDROCHLORIDE) SOLUTION [PFIZER LABORATORIES DIV PFIZER INC] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines